RODGER MACARTHUR, Wayne State University, Detroit REFERENCE: Lancet 2006; 368: 2125-35 A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST s
RODGER MACARTHUR, Wayne State University, Detroit
REFERENCE: Lancet 2006;368: 2125-35A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST study had three arms which included non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or both, all in the presence of nucleoside reverse transcriptase inhibitors. Derek Thorne heard more fromRodger MacArthurof Wayne State University in Detroit.
Related Episodes
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu